Replimune falls after FDA's Makary defends decision on cancer drug

Replimune

05/05/2026 16:05

** Shares of Replimune REPL.O fall 7.8% to $2.79

** U.S. FDA Commissioner Marty Makary defends the agency's decision to not approve Replimune's cancer drug, on CNBC

** Makary adds three independent review teams reached the same conclusion

** Last month, the health regulator declined to approve Replimune's drug advanced skin cancer, Tudriqev, for the second time

** Co says it disagrees with the FDA and plans to initiate another late‑stage trial to try to meet approval requirements

** U.S. Health Secretary Robert F. Kennedy Jr at a Senate hearing in April said he had nothing to do with the FDA's decision

** Including session moves, stock down ~71% YTD

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))